Printer Friendly

PROTEIN DESIGN LABS ANNOUNCES START OF HUMAN CLINICAL TRIALS FOR SMART M195 ANTIBODY TO TREAT MYELOID LEUKEMIA

 PROTEIN DESIGN LABS ANNOUNCES START OF HUMAN CLINICAL TRIALS
 FOR SMART M195 ANTIBODY TO TREAT MYELOID LEUKEMIA
 MOUNTAIN VIEW, Calif., Sept. 22 /PRNewswire/ -- Protein Design Labs (PDL) (NASDAQ: PDLI) announced today that the second of the company's humanized antibodies has entered human clinical trials.
 The Phase I clinical trial of PDL's SMART(TM) M195 Antibody for acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) has begun at the Memorial Sloan-Kettering Cancer Center in New York.
 There are about 15,000 new cases of these blood cancers each year in the United States, and despite best current therapy, the prognosis is usually poor. PDL plans to market the SMART M195 Antibody in the United States. Under a licensing agreement signed in March 1992, the Japanese pharmaceutical company Kanebo, Ltd. will market the drug in Asia.
 The SMART M195 Antibody was developed by PDL, and studied in collaboration with investigators at Sloan-Kettering. PDL used its proprietary technology to convert the mouse monoclonal M195 antibody developed at Sloan-Kettering, which had shown promising results in previous clinical trials, into the human-like SMART M195 Antibody. The company believes that SMART M195 Antibody will have superior therapeutic properties to the mouse antibody in human patients.
 A Physician's Investigational New Drug (IND) Application was filed with the Food and Drug Administration (FDA) to permit the clinical trial of SMART M195. The trial is being conducted by Dr. David Scheinberg and colleagues, who earlier had developed and tested the mouse M195 antibody. Phase I clinical trials measure the safety of a drug at several dosage levels.
 PDL has corporate partnerships with Hoffmann-La Roche Inc. (certain autoimmune conditions), Sandoz Pharmaceuticals (certain cancers), and Yamanouchi Pharmaceutical Co. Ltd. (cardiovascular), in addition to Kanebo, Ltd.
 Protein Design Labs, founded in 1986, is engaged in the computer- based design of antibodies and other novel proteins to treat various disease conditions, including viral infections, autoimmune disease and cancer. The company's initial product development focus is on SMART Antibodies, which combine the binding sites of a mouse antibody with a large part of a human antibody.
 PDL believes that SMART Antibodies, which are designed using the company's proprietary computer modeling techniques, will overcome the limitations of mouse antibodies and will have greatly increased effectiveness in human patients. Mouse antibodies have the potential to be effective in fighting a number of major diseases. However, the human immune system recognizes injected mouse antibodies as foreign proteins and produces an immune response that neutralizes them. PDL believes its proprietary technology will eliminate or substantially reduce this so- called human anti-mouse antibody (HAMA) response in humans.
 PDL's first product, the SMART Anti-Tac Antibody, entered Phase I clinical trials in January 1992, and by June 12 patients, the planned number, had been treated. Results are expected to be released before the year end. The SMART Anti-Tac Antibody has been licensed to Hoffman- La Roche and has potential for the treatment of graft-versus-host disease, organ transplant rejection, and certain autoimmune diseases and blood cancers.
 -0- 9/22/92
 /CONTACT: Laurence Jay Korn, Ph.D., president and CEO of Protein Design Labs, 415-903-3700/
 (PDLI) CO: Protein Design Labs ST: California IN: MTC SU: PDT


LD-TM -- SJ002 -- 1966 09/22/92 07:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1992
Words:533
Previous Article:INVESTING IN THE RIGHT MONEY MANAGER: AN IMPORTANT FIRST STEP IN TRUSTING YOUR MONEY WITH OTHERS
Next Article:FAMILIES FIND A WINTER VACATION WONDERLAND AT BEAUTIFUL CANAAN VALLEY RESORT
Topics:


Related Articles
PDL HUMANIZED ANTIBODY FOR MYELOID LEUKEMIA IS SAFE AND CAUSES NO IMMUNE RESPONSE IN PHASE I TRIAL
PROTEIN DESIGN LABS REPORTS FIRST QUARTER 1994 FINANCIAL RESULTS
Protein Design Labs Announces Results From Phase II Study of PROTOVIR(TM) in Bone Marrow Transplantation
Protein Design Labs Announces Presentation of Clinical Results With SMART M195 Antibody at ASCO Meeting.
Protein Design Labs Announces Phase III Trial Of SMART M195 Antibody.
Protein Design Labs licenses development rights to leukemia antibody.
Protein Design Labs Licenses Development Rights to SMART(TM) M195 Antibody To Actinium Pharmaceuticals; Humanized Antibody Will Be Conjugated with...
Ipilimumab (MDX-010) Safety and Clinical Response Data in Lymphomas and Leukemia Presented at the 48th American Society of Hematology Annual Meeting.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters